Lunevia logo

Research

Compound Research

Review source-grounded research summaries, evidence classifications, limitations, and registered trials.

Compound research

One canonical approved research record powers this product page, the Compound Directory, the Research Library, and related article pages.

Open compound profile

Evidence summary

Evidence supporting each component is primarily preclinical (in vitro and animal) and mechanistic, with growing formulation/delivery research for topical GHK‑Cu (doi-7197366080c5ca36; doi-64957c1ef853cc9d). Registry records indicate ongoing or planned early‑phase human studies for GHK‑Cu and BPC‑157, but no posted clinical results were included among the supplied records. For TB‑500/TB4, the supplied human data is sparse and includes at least one completed trial record without posted outcomes (trial-dd0d1f75c9f563a8). Overall, there is insufficient clinical evidence in the supplied sources to support efficacy or safety of the marketed three‑peptide blend in humans.

Investigated pathways

GLOW is a commercial combination of three peptides (GHK‑Cu, BPC‑157, TB‑500). There are no supplied primary studies testing the three‑peptide blend as a single intervention. Mechanistic rationale for the blend is inferred from separate preclinical literature for each component: GHK‑Cu is reported to modulate gene expression related to collagen/proteoglycan synthesis, angiogenesis, antioxidant and anti‑inflammatory pathways (doi-02c27699; doi-51cf1b98375fac3d); BPC‑157 is described in animal models to promote cytoprotection, angiogenesis (VEGF‑linked), fibroblast migration and modulation of inflammatory responses (doi-3edf3bd9318f3ad2; doi-e45b177a84e31df8); TB‑500 (a thymosin beta‑4 fragment) is reported to support actin dynamics, cell migration, angiogenesis and anti‑fibrotic effects in preclinical literature (doi-16e6d8ccee8b0df0). These mechanisms are complementary in that each component has been associated (in separate studies) with processes relevant to tissue repair: angiogenesis, cell migration/proliferation, extracellular matrix remodeling, and modulation of inflammation.

Preclinical evidence

All three components have a substantive preclinical literature (in vitro and animal) showing effects on wound healing–relevant endpoints. GHK‑Cu: multiple laboratory and animal reports indicate stimulation of collagen and proteoglycan production, improved fibroblast/keratinocyte function, antioxidant activity, and angiogenesis (doi-02c27699; doi-51cf1b98375fac3d; doi-7197366080c5ca36). BPC‑157: numerous animal studies report cytoprotective and regenerative effects across gastrointestinal, musculoskeletal and neural models, including tendon and liver injury models (doi-3edf3bd9318f3ad2; doi-e45b177a84e31df8), with mechanistic data implicating VEGF signaling and cell‑migration pathways. TB‑500 / TB‑4: preclinical work (and reviews) describe effects on actin dynamics, cell migration, angiogenesis and reduced fibrosis; some delivery/scaffold approaches have been evaluated in wound contexts (trial-dd0d1f75c9f563a8; doi-16e6d8ccee8b0df0).

Human evidence

There are no published randomized controlled trials or peer‑reviewed positive clinical outcome reports provided for the three‑peptide blend. For individual components, human evidence is limited and currently mainly registry/early trial activity without posted results: GHK‑Cu has active/registered clinical studies (trial-ccb8a743da81320a / NCT07706361 measuring circulating GHK/GHK‑Cu; trial-f2d77af3b8b5612c / NCT07437586 Phase 2 topical wound healing study) but no results available in the supplied records. BPC‑157 has Phase I/II trials registered (trial-f8d6323ffc71e7ca / NCT02637284; trial-f6808caf91c1c4e4 / NCT07437547) with no posted results in the supplied data. TB‑500 has limited clinical records in the supplied set: one completed small clinical scaffold study using TB4 in a slow‑release sponge (trial-dd0d1f75c9f563a8 / NCT02668055) but no posted results; a clinical trial entry labeled as illustrative/fictional (trial-952d690b40213e68) should not be treated as evidence. A recent review included in the set highlights that translational clinical evidence is lacking and that reliance upon unregulated market use is currently common (doi-16e6d8ccee8b0df0).

Evidence limitations

No supplied primary clinical results for the blend or for most component trials. Many component data are from in vitro, animal, formulation or review literature. Several supplied clinical trial records are recruiting/not yet recruiting or lack posted results. One trial entry provided for TB‑500 was explicitly described as fictional and must not be treated as evidence. Safety, dosing, pharmacokinetics, and long‑term effects in humans are not established in the supplied material. Market availability via unregulated channels presents additional concerns noted in a supplied review (doi-16e6d8ccee8b0df0).

Research areas

Randomizedcontrolled clinical trials of each component (GHK‑CuBPC‑157TB‑500) for specific wound/injury endpointsComparative studies to evaluate additive or synergistic effects when components are combined vs single agentsPharmacokineticssystemic exposure and safety profiling in humans (controlled Phase I studies)Topical and advanced delivery systems for GHK‑Cu to overcome skin permeation and stability barriersStandardized product quality and impurity assessments for peptides sourced from non‑regulated channels

Registered clinical trials

All trials

NCT07437586 · RECRUITING

Topical GHK-Cu Gel for Acute Skin Wound Healing

This study will evaluate whether a topical gel containing GHK-Cu (a copper(II)-peptide complex) can safely speed up healing of small, standardized skin wounds in healthy adults compared with a matching vehicle gel. Participants will receive two small punch-biopsy wounds on the upper arm; each wound will be randomly assigned to receive GHK-Cu gel or vehicle gel under identical dressings. Wounds will be photographed and assessed over 3 weeks, with a follow-up visit to evaluate scar quality.

Registry record

NCT07437547 · RECRUITING

BPC 157 for Acute Hamstring Muscle Strain Repair

This randomized, double-blind, placebo-controlled Phase 2 study evaluates whether pentadecapeptide BPC 157 (BPC-157), an investigational peptide, can speed structural healing and functional recovery after an acute grade II hamstring muscle strain. Participants will receive BPC 157 or placebo for 14 days in addition to a standardized rehabilitation program. The co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at Day 14.

Registry record

NCT07487363 · RECRUITING

TB-500 (Thymosin Beta 4 17-23 Fragment) for Cardiovascular Biomarkers in Stable ASCVD

This fictional study is an example of a ClinicalTrials.gov-style record. It describes a Phase 1/2 trial evaluating the safety and tolerability of TB-500 (a 17-23 fragment of thymosin beta 4) versus placebo in adults with stable atherosclerotic cardiovascular disease (ASCVD). Exploratory endpoints assess vascular function and inflammation biomarkers

Registry record

NCT02668055 · COMPLETED

Slow-release Tb4 Collagen and Chitosan Porous Sponge Scaffolds Skin Substitute Treatment is Difficult to Heal Wounds

Evaluation of slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitutes the effectiveness of clinical trials for the treatment of difficult to heal wounds and security.

Registry record

Related research articles

GHK-Cu may Prevent Oxidative Stress in Skin by Regulating Copper and Modifying Expression of Numerous Antioxidant Genes

A review compiling preclinical data that GHK‑Cu stimulates ECM production, angiogenesis and antioxidant defenses in skin and other tissues, and that it modulates gene networks linked to repair.

Read summary

Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application

Formulation work producing cationic and anionic liposomes entrapping GHK‑Cu for topical applications; investigated encapsulation efficiency, bilayer properties and enzyme inhibition relevant to skin aging.

Read summary

70% Liver Resection in Rats. Pentadecapeptide BPC 157 Beneficial Effect Counteracts Worsening Induced by L-NAME

An animal model study where BPC‑157 improved liver recovery metrics and mitigated the worsening effects of nitric oxide synthase inhibition after major hepatic resection in rats.

Read summary

Review of peptide bioregulators for recovery after sports injuries (BPC-157, TB-500)

A critical review contrasting robust preclinical data for BPC‑157 and TB‑500 with the absence of high‑quality human RCT evidence, and discussing regulatory and safety concerns around grey‑market peptide use.

Read summary
Educational summaries describe published research cautiously and do not make diagnostic, treatment, dosing, cure, or human-use claims. Human, animal, in-vitro, computational, and review evidence are identified separately. Registered trials are not the same as published results. Last reviewed: Not recorded.

Related products